Webinars

DEC 09, 2015 10:00 AM PST

WEBINAR: Emerging Trends in Heart Failure Therapy and the Importance of Natriuretic Peptides

Sponsored by: Roche Diagnostics, Roche Diagnostics

Speaker

Robert Fitzgerald, PhD

Professor, Department of Pathology, Director of the Toxicology Laboratory, Associate Director of the Clinical Chemistry Lab, University of California, San Diego
BIOGRAPHY

Event Date & Time

Date: December 9, 2015 10AM Pacific, 1PM Eastern

Abstract

July 7, 2015, the U.S. Food and Drug Administration reviewed and approved ENTRESTO™ (sacubitril/valsartan) tablets to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. This important news could shift the paradigm in the way heart failure patients will be managed using NT-proBNP in lieu of BNP for patients receiving ENTRESTO™.

In this webinar, we will discuss the analytical and clinical considerations of NT-proBNP testing and the impact of ENTRESTO™ on biomarker testing.

Learner Objectives:

• Describe differences in stability of NT-proBNP and BNP
• Describe the analytical differences between NT-proBNP and BNP assays
• Describe how natriuretic peptides compare in the setting of renal failure
• Describe the mechanism of action of ENTRESTO™ and it’s effect on natriuretic peptides

WEBINAR: Emerging Trends in Heart Failure Therapy and the Importance of Natriuretic Peptides

Robert Fitzgerald, PhD